Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsGlobeNewsWire • Thursday
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyGlobeNewsWire • 04/22/24
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia CardiomyopathyGlobeNewsWire • 04/16/24
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingGlobeNewsWire • 03/13/24
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsGlobeNewsWire • 03/11/24
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsGlobeNewsWire • 02/05/24
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)GlobeNewsWire • 12/18/23
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 12/11/23
Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below rangeMarket Watch • 11/03/23